Moderna Inc Cash Flow-to-Debt Ratio
Moderna Inc cash flow-to-debt ratio. Moderna Inc (MRNA) has a Cash Flow-to-Debt Ratio of -0.13x as of June 2026, meaning its operating cash flow of $-526.00 Million could theoretically repay 0% of its total liabilities ($4.20 Billion) in one year. Check Moderna Inc (MRNA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Moderna Inc (2014–2025)
Cash flow-to-debt ratio of Moderna Inc from 2014 to 2025. Historical debt coverage capacity for Moderna Inc across 12 annual periods. Check MRNA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Moderna Inc Cash Flow-to-Debt Ratio by Year (2014–2025)
Moderna Inc cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Moderna Inc. For the full cash flow conversion analysis, see MRNA cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.51x | $-1.87 Billion | $3.69 Billion | ▲ +45.2% |
| 2024 | -0.93x | $-3.00 Billion | $3.24 Billion | ▼ -35.9% |
| 2023 | -0.68x | $-3.12 Billion | $4.57 Billion | ▼ -192.2% |
| 2022 | 0.74x | $4.98 Billion | $6.74 Billion | ▼ -42.9% |
| 2021 | 1.29x | $13.62 Billion | $10.52 Billion | ▲ +204.9% |
| 2020 | 0.42x | $2.03 Billion | $4.78 Billion | ▲ +138.3% |
| 2019 | -1.11x | $-458.97 Million | $414.61 Million | ▼ -44.5% |
| 2018 | -0.77x | $-330.87 Million | $431.91 Million | ▼ -6.1% |
| 2017 | -0.72x | $-331.48 Million | $459.19 Million | ▼ -722.3% |
| 2016 | 0.12x | $66.73 Million | $575.31 Million | ▲ +102.7% |
| 2015 | -4.30x | $-738.15K | $171.66K | ▼ -1122.5% |
| 2014 | -0.35x | $-4.78 Million | $13.59 Million | — |